Contents

List of Contributors  XI
Preface  XV

1 Biomarkers – Past and Future  1
Siegfried Neumann

1.1 Introduction  1
1.2 Definitions of Biomarkers  2
1.3 Biomarkers in the Past  3
1.4 Novel Molecules and Structural Classes of Biomarkers by New Technologies  7
1.5 Biomarkers in Drug Research  9
1.6 Current Development and Future Trends for Biomarkers in Laboratory Diagnostics  12
1.6.1 Biomarker Test Validation  12
1.6.2 Companion Diagnostics in Clinical Pharmacology  14
1.6.3 Biomarker Multivariate Index Assays  16
1.6.4 Regulatory Policies on Biomarker Tests  17
1.7 Summary and Outlook  19
References  20

2 Quantitative Proteomics Techniques in Biomarker Discovery  23
Thilo Bracht, Dominik Andre Megger, Wael Naboulsi, Corinna Henkel, and Barbara Sitek

2.1 Introduction  23
2.1.1 General Considerations  24
2.2 2D-Difference Gel Electrophoresis  27
2.3 Mass Spectrometry-Based Proteomics  29
2.3.1 Principles and Instrumentation  29
2.3.1.1 Ionization Methods  29
2.3.1.2 Mass Analyzers  30
2.3.2 Label-Free Protein Quantification  30
2.3.2.1 Area Under Curve (AUC) or Signal Intensity Measurement  30
2.3.2.2 Spectral Counting  31
2.3.3 Label-Based Proteome Analysis 31
2.4 MALDI Mass Spectrometry Imaging 33
2.5 Conclusion 36
References 36

3 Biomarker Qualification: A Company Point of View 39
Maximilian Breitner, Kaidre Bendjama, and Hüseyin Firat
3.1 Introduction 39
3.2 Biomarker Uses 40
3.3 Biomarker Types 41
3.4 Validation vs. Qualification 43
3.5 Strategic Choices in Business Models 43
3.6 Validation of Analytical Methods 44
3.6.1 Currently Applicable Guidelines for the Validation of Analytical Methods 45
3.6.2 Laboratory Proficiency 46
3.6.3 Establishment of Reference Ranges for Candidate Biomarkers 46
3.7 Clinical Qualification of Candidate Biomarkers 47
3.7.1 Methodological Approaches 47
3.7.2 Study Size for Biomarker Performance Characterization 48
3.7.3 Sample Quality and Biobanking 50
3.7.3.1 Sample Collection 50
3.7.3.2 Storage of Sample 51
3.7.3.3 Clinical Data (Sample Annotation) 52
3.7.3.4 Ethical Considerations 53
3.8 Biomarker Qualification in the 'omics Era 53
3.9 An Example of a Biomarker Provider 54
3.10 Conclusion 55
References 55

4 Biomarker Discovery and Medical Diagnostic Imaging 59
Andreas P. Sakka and James R. Whiteside
4.1 Introduction 59
4.1.1 Imaging Modalities 59
4.1.1.1 Positron Emission Tomography (PET) 59
4.1.1.2 Single Photon Emission Computed Tomography (SPECT) 60
4.1.1.3 Computed Tomography (CT) 60
4.1.1.4 Magnetic Resonance Imaging (MRI) 60
4.1.1.5 Ultrasound (US) 61
4.2 Factors to Consider in Biomarker Selection for Imaging 61
4.3 Defining the Insertion Point of the Assay and Its Business Case 62
4.4 Practical In Vitro Methods Used to Identify Biomarkers 63
4.5 Preclinical Models 64
4.5.1 Model Species 64
7 Bone Remodeling Biomarkers: New Actors on the Old Cardiovascular Stage 107
Cristina Vassaile, Silvia Maffei, and Giorgio Iervasi
7.1 Introduction 107
7.2 Cardiovascular Disease and Osteoporosis: Common Risk Factors and Common Pathophysiological Mechanisms 108
7.3 Biomarkers of Bone Health in CVD 112
7.3.1 Cathepsin K 112
7.3.2 Tartrate-Resistant Acid Phosphatase 115
7.3.3 Sclerostin 115
7.3.4 Fibroblast Growth Factor 23 116
7.3.5 Osteopontin 116
7.3.6 Osteocalcin 117
7.3.7 Osteoprotegerin 118
7.3.8 Vitamin D 120
7.3.9 Other Factors 121
7.3.10 Genetic Factors 123
7.4 Conclusion 125
References 128

8 Identification and Validation of Breast Cancer Biomarkers 147
Kori Jackson and Edward Sauter
8.1 Introduction 147
8.2 Current Detection and Treatment Modalities 148
8.2.1 Detection: In Clinical Use 148
8.2.1.1 Physical Examination 148
8.2.1.2 Breast Imaging 148
8.2.2 Detection: Being Evaluated 149
8.2.2.1 Bodily Fluid Analyses 150
8.2.3 Treatment: In Clinical Use 150
8.2.3.1 Surgery and Radiation 150
8.2.3.2 Systemic Therapy 151
8.2.4 Treatment: Being Evaluated/Newly Available 153
8.2.4.1 Biomarkers in Tissue: Single Markers 153
8.2.4.2 Biomarkers in Tissue: Gene Panels 154
8.3 Current Biomarker Limitations 154
8.3.1 Tumor Heterogeneity 154
8.3.2 Treatment Effect 155
8.3.3 Primary Versus Recurrent Tumor 155
8.4 Future Biomarker Discovery Targets 156
8.4.1 Autoantibodies 156
8.4.2 Inflammatory Markers 156
8.4.3 DNA Methylation 157
8.4.4 Benign Breast Disease 157
8.4.5 Pregnancy-Associated Breast Cancer 157